| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.60(B) |
| Last
Volume: |
14,535,649 |
Avg
Vol: |
11,963,293 |
| 52
Week Range: |
$43.67 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
18,718 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$1,146,397 |
$49,727,684 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
12 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Biondi Paul |
SVP, Head of Strategy & BD |
• – – |
2019-10-02 |
4 |
D |
$49.21 |
$9,990 |
D/D |
(203) |
6,214 |
|
- |
|
| Biondi Paul |
SVP, Head of Strategy & BD |
• – – |
2019-10-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
592 |
6,417 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2019-09-01 |
4 |
D |
$48.07 |
$10,575 |
D/D |
(220) |
3,487 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2019-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
641 |
3,707 |
|
- |
|
| Bertolini Robert J |
Director |
– • – |
2019-07-31 |
4 |
B |
$44.72 |
$491,920 |
D/D |
11,000 |
11,397 |
2.39 |
- |
|
| Eid Joseph |
SVPHead Global Medical Affairs |
• – – |
2019-06-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,170 |
|
- |
|
| Judge Ann Powell |
SVP, Global Human Resources |
• – – |
2019-06-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(41,546) |
31,826 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2019-05-16 |
4 |
S |
$47.56 |
$145,771 |
D/D |
(3,065) |
3,066 |
|
- |
|
| Samuels Theodore R. Ii |
Director |
– • – |
2019-05-16 |
4 |
B |
$47.29 |
$236,440 |
D/D |
5,000 |
27,000 |
2.39 |
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2019-05-05 |
4 |
D |
$48.62 |
$134,872 |
D/D |
(2,774) |
368,066 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2019-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,399) |
370,840 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2019-05-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,040 |
373,239 |
|
- |
|
| Lynch Thomas J. Jr. |
EVP & Chief Scientific Officer |
• – – |
2019-04-03 |
4 |
D |
$46.88 |
$289,296 |
D/D |
(6,171) |
22,223 |
|
- |
|
| Lynch Thomas J. Jr. |
EVP & Chief Scientific Officer |
• – – |
2019-04-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(773) |
25,043 |
|
- |
|
| Lynch Thomas J. Jr. |
EVP & Chief Scientific Officer |
• – – |
2019-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,594 |
25,816 |
|
- |
|
| Bancroft Charles A |
EVP & Chief Financial Officer |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$1,254,070 |
D/D |
(24,403) |
395,994 |
|
- |
|
| Bancroft Charles A |
EVP & Chief Financial Officer |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,255 |
411,547 |
|
- |
|
| Bancroft Charles A |
EVP & Chief Financial Officer |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,735) |
376,895 |
|
- |
|
| Dubow Adam |
Chief Compliance & Ethics Offi |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$60,743 |
D/D |
(1,182) |
17,489 |
|
- |
|
| Dubow Adam |
Chief Compliance & Ethics Offi |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,735 |
18,240 |
|
- |
|
| Dubow Adam |
Chief Compliance & Ethics Offi |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(286) |
16,153 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$408,448 |
D/D |
(7,948) |
9,386 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,707 |
14,501 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,247) |
5,933 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$61,462 |
D/D |
(1,196) |
6,131 |
|
- |
|
2225 Records found
|
|
Page 17 of 89 |
|
|
0.35 (0.78%) 
